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Abstract
Exposure to neurotoxic chemicals such as pesticides, selenium, and heavy metals have been 
suggested to play a role in the etiology of amyotrophic lateral sclerosis (ALS). We assessed 
exposure to lead, cadmium, and mercury in 38 ALS patients (16 men and 22 females) and 38 
hospital-admitted controls by using their cerebrospinal fluid (CSF) content as biomarker. We 
determined CSF heavy metal levels with inductively coupled plasma sector field mass 
spectrometry, according to a methodology specifically developed for this biological matrix. ALS 
patients had higher median values for Pb (155 vs. 132 ng/l) but lower levels for Cd (36 vs. 72 ng/l) 
and Hg (196 vs. 217 ng/l). In the highest tertile of exposure, ALS odds ratio was 1.39 (95% CI 
0.48 to 4.25) for Pb, 0.29 (0.08 to 1.04) for Cd and 3.03 (0.52-17.55) for Hg; however, no dose-
response relation emerged. Results were substantially confirmed after conducting various 
sensitivity analyses, and after stratification for age and sex. Though interpretation of these results 
is limited by the statistical imprecision of the estimates, and by the possibility that CSF heavy 
metal content may not reflect long-term antecedent exposure, they do not lend support to a role of 
the heavy metals cadmium, lead and mercury in ALS etiology.
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Introduction
The etiology of amyotrophic lateral sclerosis (ALS), an extremely severe neurodegenerative 
disease which selectively affects both the upper and the lower motor neurons, is still 
unknown, though in the so-called familial form (around 10% of cases) a few gene mutations 
appear to play a major role [1, 2].
The etiology of the disease is still largely unknown, and environmental factors, alone or in 
the presence of particular genetic backgrounds, are believed to play a major role in it [2-7]. 
These environmental factors include neurotoxic chemicals, such as pesticides, the metalloid 
selenium and a few heavy metals [4, 8, 9]. Among the latter, lead, cadmium, and mercury 
have been implicated in ALS etiology following toxicological and epidemiological 
observations [8, 10, 11]. However, such evidence linking exposure to these metals to ALS is 
not consistent, and major methodological issues, particularly concerning exposure 
assessment and the potential for bias due to unmeasured confounding have been raised 
concerning these investigations [9]. In this study, we aimed at assessing a biomarker of 
heavy metal antecedent exposure, its cerebrospinal fluid (CSF) content, and its potential 
relation with ALS risk.
Methods
Study population
The study population (composed of 38 ALS cases and 38 controls) and details of case 
identification, their clinical characteristics and sampling procedure have been previously 
described in detail [12]. Briefly, all cases: resided in the Emilia-Romagna region, northern 
Italy; received a diagnosis of clinically definite or probable ALS using the revised El 
Escorial Criteria [13] at the ALS Center in Modena, from May 1998 to April 2011; 
underwent lumbar puncture during diagnostic evaluation; and had at least 1 ml CSF 
available when the present study was designed. Twelve of these patients (generally the 
youngest ones) also received extensive genetic screening, showing no positivity for the 
major genes involved in familial ALS (namely SOD1, C9ORF72, FUS, TDP43). The 
controls: were patients admitted to the same hospital between 1999 and 2010; resided in the 
Emilia-Romagna region; underwent lumbar puncture due to suspected neurological disease; 
were subsequently found not to be affected by neurological disease; and had a CSF sample 
of 1 mL or more available in September 2011. We randomly selected among these eligible 
persons 38 individuals, matched 1:1 to ALS cases on age (± 10 years, generally ± 5 years) 
and gender. These individuals were referred to neurological examination due to headache 
(n=17), paresthesias (n=5), diplopia (n=6), vertigo (n=3) and other signs and symptoms 
(n=7).
Study participants underwent lumbar puncture for CSF sampling after providing their 
informed consent, and use of samples for research purposes was later approved by the 
Modena Ethical Committee. Around 6 mL of CSF were obtained from each participant 
using an ultraclean procedure, and the sample was immediately stored at -80°C in 
polypropylene tubes. When the study was designed, a 1-ml aliquot was transported deep 
frozen in dry ice to the Munich Helmoltz Zentrum laboratory, and kept continuously frozen 
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until use. When the analytical phase was started, the samples were slowly thawed in a 
refrigerator at 4 °C, vortexed and then analysed.
Laboratory analyses
We determined the CSF levels of Cd, Hg and Pb using a previously described methodology 
[14-16]. Briefly, we slowly thawed the samples in a refrigerator to 4°C, vortexed and 
subsequently diluted samples 1:10 with Milli-Q water, containing 103Rh as internal standard 
at a final concentration CSF of 1 μg/L in the diluted CSF samples. Element concentrations of 
CSF samples were determined using inductively coupled plasma–mass spectrometry: An 
NexIon, ICP-MS instrument (Perkin Elmer, Rodgau-Jügesheim Germany) was employed 
for 111Cd, 202Hg, and 208Pb determination. Sample introduction was carried out using the 
instrument's peristaltic pump connected to a Micromist nebulizer with a cyclone spray 
chamber. The RF power was set to 1250 W, the plasma gas was 15 L Ar/min, whereas the 
nebulizer gas was approximately 0.9 L Ar/min after daily optimization.
These determination methods had been validated by regular laboratory intercomparison 
studies (GEQUAS quality control scheme and participation in certification campaign of 
IRMM/EU) and by regular analysis of adequate certified reference materials. Along the 
analysis of samples several certified reference materials (CRM) were analysed (expressed as 
certified value/detected value). For Cd: ERM-BD-150: 11.4 ± 2.9 μg/kg / 11.4 ± 0.5 μg/kg 
(corresponding to 31 ng/L Cd in measurement solution); ERM-DB-001: 125 ± 7 μg/kg / 123 
± 2.9 μg/kg (corresponding to 330 ng/L Cd in measurement solution); BCR-635: 6.6 ± 0.6 
μg/L / 6.57 ± 0.16 μg/L. For Pb: ERM-BD-151: 207 ± 14 μg/kg / 204.4 ± 2 μg/kg 
(corresponding to 2 μg/L Pb in measurement solution), ERM-DB-001: 2.14 ± 2 mg/kg / 2.34 
± 0.19 mg/kg (corresponding to 23 μg/L Pb in measurement solution); BCR-635: 210 ± 24 
μg/L / 220 ± 5 μg/L. For Hg: ERM-BD-150: 0.0603 ± 0.0178 μg/kg / 0.073 ± 0.0131 μg/kg 
(corresponding to 1 ng/L Hg in measurement solution), ERM-BD-151: 0.052 ± 0.04 μg/kg / 
0.51 ± 0.001 μg/kg (corresponding to 5 ng/L Hg in measurement solution). The limit of 
quantification of the determination method was 18 ng/L for Cd and 20 ng/L for Pb and Hg, 
each related to undiluted CSF. Coefficient of variation was for Cd 2.1 %, for Pb 2.7 %, and 
for Hg 1.9 % (n=10, each).
According to IUPAC recommendations, accuracy should be derived from comparison with 
CRM. For Cd, accuracy was derived from CRM ERM-BD 150 as the measurement 
concentration (∼30 ng/L) was about the lower concentrations in CSF. Accuracy for Cd was 
determined at 100 % (11.4 μg/kg / 11.4 μg/kg). For, Hg, accuracy was derived from CRM 
ERM-BD 151 since measurement concentrations in digests were approximately the same as 
in low concentrated diluted CSF samples. Accuracy for Hg was determined at 98 % (0.52 
μg/kg / 0.51 μg/kg). Lead accuracy was derived from the same CRM. For Pb, accuracy was 
determined at 99 % (207 μg/kg / 204.4 μg/kg).
Data analysis
We carried out data analysis independently for each of the three heavy metals under 
examination based on CSF concentration tertiles computed from the controls. Using 
unconditional logistic regression models, we computed the odds ratio (OR) for ALS with its 
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95% confidence interval (CI) for each of the highest two concentration tertiles, compared 
with the lowest tertile. We fit crude models, along with models adjusted for sex and age (in 
years, continuous), and then models additionally adjusted for total CSF selenium content 
([units], continuous). We also computed a P value for trend based on the continuous values 
of heavy metal exposure. We eventually carried out several sensitivity analyses: removing 
from data analysis controls characterized by specific symptoms and signs (i.e., the 17 
subjects suffering from headache, the 5 affected by paresthesias and the 6 affected by 
diplopia); adjusting for the other two remaining metals investigated; using log-transformed 
values or winsorized values by setting data exceeding the 95th percentile to the 95th 
percentile; fitting conditional logistic regression models based on the age- and sex-based 
matching; and assigning exposure category on the basis of pre-specified fixed cutpoints of 
CSF metal content instead of tertiles.
Results
The newly-diagnosed ALS cases included 16 men and 22 women, with a mean age of 55 
years (range 30-76 years), in 7 cases characterized by bulbar onset disease and in 31 by 
spinal onset ALS. The 38 sex- and age-matched controls had a mean age of 52 years, 
ranging from 30 to 85 years. Table 1 and Figure 1 summarize the distribution of heavy 
metals with reference to their median concentration, and their 10° and 90° percentiles. 
Median CSF concentrations in cases compared with controls were higher for lead, slightly 
lower for mercury and considerably lower for cadmium, with an interquartile range 
systematically wider for all the three metals.
Odds ratios (ORs) of ALS according to heavy metal CSF concentrations are shown in Table 
2. The odds of ALS were greater in the highest tertile of CSF Pb concentration than in the 
lowest tertile (OR=1.4 in both multivariable-adjusted models), though confidence interval 
were rather wide (e.g., 95% CI, 0.46 to 4.17 in age- and sex-adjusted results). However, 
there was no appreciable trend of the OR across tertiles, since it was below the unity in the 
middle category of exposure, and this was confirmed by the trend analysis based on 
continuous levels of exposure. Concerning Cd exposure, OR decreased in the middle and 
highest tertiles, and the analysis for linear trend based on continuous values confirmed an 
inverse association between exposure and risk. OR associated with tertile of Hg exposure 
showed a strongly increased but very statistically unstable OR, with no evidence of any 
dose-response relation both in this analysis and in that based on continuous values of 
exposure. In this latter trend analysis, OR was 1 for both Pb and Hg, while for Cd it was 
0.99 (95% CI 0.98-1.00).
Results did not substantially change for any of the elements investigated when in 
multivariate analysis we adjusted for the remaining two heavy metals, for either inorganic or 
organic CSF selenium content instead of overall selenium level, or in stratified analysis 
according to sex or age group (using 50 years as cutpoint - data not shown). Results also 
showed little variation when we used log-transformed values or winsorized values, using 
conditional logistic regression instead of the unconditional one, assigning exposure category 
on pre-specified CSF heavy metal cutpoints, or removing control subjects characterized by 
specific symptoms or signs (data not shown).
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Discussion
Overall, our results failed to show an association between heavy metals exposure, as 
reflected by CSF content, and increased risk of ALS. This was substantially true for all the 
heavy metals investigated in this study, since there was no detectable dose-response trend of 
increased ALS risk across tertiles or continuous values of exposure, and this was confirmed 
in both stratified and sensitivity analyses. However, while lack of association was clearly 
evident for Cd and appears to rule out any association of the disease under study with such 
exposure, results for Pb and Hg are more difficult to interpret. For Pb, there was a slight 
increase in the top category of exposure, though the relative risk estimate was statistically 
unstable and the analysis based on continuous values did not suggest an association. In 
adjusted analyses of Hg, those in the middle tertile of exposure had 12 times the odds of 
ALS compared with those in lower tertile, but in the highest tertile, the OR was much 
smaller. This pattern and the absence of linear dose-response association in the analyses of 
continuous Pb concentration provide little support for a real etiological association.
The literature about the involvement of Pb, Cd and Hg in ALS etiology is conflicting, 
though some suggestive evidence particularly for Pb have been provided. All the three 
elements have the toxicological potential for damaging neural cells, through mechanisms 
ranging from glutamate-induced neurotoxicity, oxidative stress, protein misfolding, altered 
RNA and protein synthesis and aggregation, and they may induce inflammation, axonal and 
mitochondrial transport dysfunction, and cell death thus providing biological plausibility for 
an association with ALS [8]. In addition, there is evidence that these metals may cross the 
blood-brain and blood-CSF barriers, particularly in diseased individuals, and/or may 
undergo retrograde axonal transport, and thus reaching the target tissues for 
neurodegeneration [8, 17]. In addition, none of these three heavy metals has a peculiarly 
selective toxicity for the motor neurons among the various neural cells, a distinctive feature 
of another neurotoxicant (which however also is an essential element) implicated in ALS 
etiology, selenium. Finally, the epidemiologic evidence linking Pb, Cd and Hg to ALS 
etiology is still sparse and rather conflicting [8], though at least for Pb most of the recent 
reports highlighted a possible association with disease risk [18-23]. One human study, 
carried out in Sweden, has specifically investigated CSF trace elements content in ALS 
patients, showing higher levels of Pb, Cd and lower concentration of Hg in cases compared 
with controls [18].
The lack of substantial association we found for the heavy metals we investigated might be 
due error in the measurement of long-term antecedent exposure by CSF heavy metal levels, 
both in cases and in controls. In general, concentrations of a chemical and particularly of 
heavy metals in the CSF and more generally in the central nervous system has the strong 
advantage, as compared with peripheral biomarkers of exposure such as their blood [24] and 
toenail [25] content, to reflect levels of the contaminant levels in a compartment closely 
related to the pathological process characterizing ALS and more generally 
neurodegenerative disease [12, 26, 27]. However, two major issues arise: the ability of Pb, 
Cd and Hg to accumulate near the blood-CSF barrier and/or to cross it, and the long-term 
persistence of an increased content of these metals in biomarkers, with particular reference 
to CSF level, after the ending of a subject's overexposure. Unfortunately, both these issues 
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are not entirely clear. For lead, there is evidence in the human that the CSF content may 
reflect plasma (though not whole blood) Pb concentration [28, 29], while such evidence for 
mercury and cadmium is anecdotal or missing, respectively [30]. However, it has been 
shown that all these three heavy metals, also depending on their speciation particularly for 
Hg [31], may accumulate in the blood-brain and particularly in the blood-CSF barrier at the 
choroid plexus, the organ which secretes CSF [32], reaching in loco high concentrations. 
Though this might represent a mechanism protecting the CSF and more generally the central 
nervous system against heavy metals [33], such a high content in the choroid plexus may 
also have adverse proteomic effects and relevant neurotoxicological implications on the 
choroid plexus itself or the brain [34-36]. In addition, there is evidence that blood-CSF 
barrier is altered in nearly half the ALS patients, and this abnormality might in turn increase 
the transfer of contaminants from the blood into the CSF [8, 37, 38]. Concerning the 
persistence of an increased CSF heavy metal content following the end of environmental 
overexposure, we were unable to find any evidence from the literature for the heavy metals 
here examined, thus hampering the evaluation of our results. Overall, if misclassification of 
exposure occurred for any of the heavy metals, it may have hampered the detection of an 
association between with ALS risk in the current study, likely for an excess time window 
between exposure ending and disease onset. This highlights the need of either prospective 
studies (though very difficult to perform if encompassing CSF sampling, also due to disease 
rarity) or further studies assessing long-term sources of exposure though retrospective 
dietary assessment or evaluation of occupational history. It is also possible that disease 
progression may alter trace element content in body tissues, altering nutritional status and 
trace element distribution in the various compartments, as suggested by some observations 
of a direct association between blood and spinal cord Pb content and ALS stage [24, 39]. 
However, it must be noted that our study was based only on newly-diagnosed ALS patients, 
thus reducing the risk of reverse causation.
The present study also suffered from a limited statistical power, due to the sample size, as 
also reflected by the wide confidence intervals of the estimates. This is in turn due to ALS 
being a rare disease, and in addition usually not requiring CSF sampling during its 
diagnostic process, and to the difficulty of finding CSF from potentially matched controls 
unaffected by neurological disease. Therefore, and under the hypothesis of a role of Pb in 
ALS etiology, it is possible that a larger study population is needed to capture statistically 
stable estimates for slightly increased risk associated to that exposure, possibly only in the 
highest exposure category. It is also possible that higher levels of exposure, for Pb but also 
for Hg, are needed to identify an association with the disease, under the hypothesis that ALS 
is a multifactorial disease with various different factors potentially playing a role in its 
etiology and that in our study population such high levels of exposure were not adequately 
represented. This might be also supported by a comparison of our results with those obtained 
in 20 control subjects from another Italian setting, who showed substantially similar CSF Cd 
concentrations but much higher Hg and Pb levels (four to six times) compared with our 
controls [40].
We did not identify reasons to hypothesize the occurrence of selection bias in our study 
populations, with reference to both cases and controls. CSF sampling was occasionally 
needed during the diagnostic process of patients later found to be affected by ALS, with no 
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apparent association whatsoever with variables (such as occupational status, smoking and 
residence) potentially associated with heavy metal exposure. This was also true for the 
control populations, which included patients reporting signs and symptoms not strongly 
associated a priori with the exposures of interest. In addition, study results were substantially 
confirmed after excluding specific subgroups of controls through sensitivity analyses.
In conclusion, we found little evidence of an increased ALS risk associated with CSF Pb, Cd 
and Hg content, with no dose-response relation. These findings do not add support to the 
hypothesis that these heavy metals are involved in disease etiology, though they must be 
evaluated with caution since the biomarker we used in the study might have been unable to 
reflect long-term antecedent exposures.
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Figure 1. Plot of CSF heavy metal concentrations, as ng/L, in controls (white) and ALS cases 
(gray)
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